IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?

@article{Rodrigues2005IMPACTOC,
  title={IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?},
  author={A. David Rodrigues},
  journal={Drug Metabolism and Disposition},
  year={2005},
  volume={33},
  pages={1567 - 1575}
}
  • A. D. Rodrigues
  • Published 1 November 2005
  • Medicine
  • Drug Metabolism and Disposition
The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance… 

Tables from this paper

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
TLDR
Clinical data regarding the impact of the CYP2C8*3 allele on the disposition of NSAIDs are conflicting and no definitive conclusions can be made at this time, but contrary to in vitro data, clinical data suggest that the CYC2C48*2 and *3 allele is associated with increased metabolism of the cytochrome P450 substrates, rosig litazone, pioglitazone and repaglinide.
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased enzyme activity are
The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
  • U. Klotz
  • Biology, Medicine
    Clinical pharmacokinetics
  • 2007
TLDR
The traditional and validated therapeutic drug monitoring approach, representing a direct ‘phenotype’ assessment, still remains the method of choice when an individualised dosing regimen is anticipated, but pharmacogenetics and pharmacogenomics can offer some novel contributions when attempts are made to maximise drug efficacy and enhance drug safety.
Pharmacogenetics of non-steroidal anti-inflammatory drugs: existing problems for clinical practice
TLDR
The pharmacogenetic predictors of adverse effects that patients can experience, and the need for dose adjustment based on the patient’s genotype, or individualizing the choice of alternative NSAIDs to increase the effectiveness of analgesia, have been determined.
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
TLDR
CYP2C9 genotyping may identify subgroups of persons who potentially are at increased risk of gastroduodenal bleeding when treated with NSAIDs metabolized by CYP2C8, and further studies that evaluate the effectiveness of a strategy using CYP 2C9genotyping in NSAID users are needed.
Clinical pharmacology of celecoxib, a COX-2 selective inhibitor
TLDR
It could be suggested that the use of low doses of celecoxib in short-treatment, especially in patients with previous experience of GI events, contribute in the decision-making process of prescribing COX-2 or NSAIDs.
Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy
TLDR
In the present review, functional changes of all known CYP2C9 protein coding alleles were predicted using in silico analyses and compared with the in vitro and in vivo data.
Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
TLDR
The half-life, oral clearance and AUC(inf) of lornoxicam were similar in individuals with CYP2C9*1/*13 and those with CYp2C 9*1*3, although C(max) was higher in CYP1*1*/13 individuals, and a CYP3*1 /*3 genotype markedly reduced the conversion of lORNoxicam to 5'-hydroxylorn Toxicam.
...
...

References

SHOWING 1-10 OF 145 REFERENCES
CYP2C9 genotype as a predictor of drug disposition in humans.
  • C. Lee
  • Biology
    Methods and findings in experimental and clinical pharmacology
  • 2004
TLDR
Findings suggest that CYP2C9 genotype-guided dosing may be clinically useful and warrants prospective investigation.
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
In-vitro data indicate major effects of the genetically polymorphic cytochrome P450 enzyme 2C9 (CYP2C9) on the pharmacokinetics of celecoxib, a nonsteroidal anti-inflammatory drug acting as selective
Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.
TLDR
Current trends in the industry have been fueled by increased managed healthcare, the desire to minimize the need for therapeutic drug monitoring and CYP genotyping in medical practice, and a very competitive market place.
Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient
Clinical Consequences of Cytochrome P450 2C9 Polymorphisms
Pharmacokinetics of Rofecoxib
TLDR
COX-2 inhibitors represent a major therapeutic advance in terms of gastrointestinal safety; however, long-term safety in other organ systems and with concomitant drug administration still remain to be proven.
Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
TLDR
Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates.
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
TLDR
New, ultrapotent inhibitors of CYP2C9 have been synthesised that aid in the development of quantitative structure-activity relationship (QSAR) models to facilitate drug redesign, and extensive resequencing of the gene and studies of its regulation will undoubtedly help to understand interindividual variability in drug response and toxicity controlled by this enzyme.
Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
TLDR
The results show that the pharmacokinetics of lornoxicam are dependent on CYP2C9 polymorphism, and the presence of the CYP1C9*3 allele impairs the oral clearance of lORNoxicam.
...
...